Bilcare Ltd (BI) — shareholding pattern, promoter holding, financials and share price
About Bilcare Ltd (BI)
Bilcare Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as BI and on the BSE under scrip code 526853. Its ISIN is INE986A01012.
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
Bilcare Ltd is engaged in manufacturing specialty pharmaceutical packaging films, providing research services, and offering clinical services.
The company has a significant history of innovation, developing novel packaging solutions to protect moisture and oxygen-sensitive pharmaceuticals, reflecting its strong R&D capabilities.
Listed peers in Healthcare Research, Analytics & Technology: Jeevan Scientific Technology Ltd, Globalspace Technologies Ltd, Novelix Pharmaceuticals Ltd, Adeshwar Meditex Ltd, Vanta Bioscience Ltd, Docmode Health Technologies Ltd.
Valuation & Returns
10 Jul 2026At ₹62.55 a share on 10 Jul 2026, Bilcare Ltd (BI) was valued at a price-to-earnings ratio of 26.99x against an industry P/E of 61.73x and a price-to-book of 0.3x on a book value of ₹211.44 per share as of Mar 2024. Solomo computes return on equity of -7.64% and return on capital employed of 2.4% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 26.99x
- Industry P/E
- 61.73x
- P/B
- 0.3x
- EPS (TTM)
- ₹-16.16
- Book value / share
- ₹211.44
- ROE
- -7.64%
- ROCE
- 2.4%
- ROA
- -2.43%
- Debt / equity
- 1.52x
- Dividend yield
- 0%
- EBITDA margin
- 9.63%
- 52-week range
- ₹50 – ₹116
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Bilcare Ltd (BI) reported revenue of ₹734 crore, net profit of ₹-17 crore and earnings per share of ₹0.73. That compares with revenue of ₹788 crore and net profit of ₹-56 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹187.66 crore and net profit ₹7.85 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 845 | 982 | 747 | 788 | 734 |
| Net profit (₹ cr) | -4 | 50 | -59 | -56 | -17 |
| EPS (₹) | -5.35 | 6.39 | -14.12 | -12.23 | 0.73 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -29.18% | -41.02% | -67.24% | 5.47% |
| Profit growth | - | - | - | 4.03% |
| Stock price CAGR | 1% | -8% | 5% | -11% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 30.01% of Bilcare Ltd (BI) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.04%. Promoters have pledged 1.4% of their holding. Market capitalisation was ₹147 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Monument Pte Limited 16.44%, Guttikonda Vara Lakshmi 14.73%, Guttikonda Rajasekhar 2.2%, Sharad Mohanlal Bhatevara 1.64%, Rajendra Bhagirath Tapadia 1.06%, Chhaganbhai Parsottambhai Patel Huf 1.03%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Mar 2026 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Dec 2025 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Sep 2025 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Jun 2025 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Mar 2025 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Dec 2024 | 30.01% | 1.4% | 0.04% | - | 69.99% |
| Sep 2024 | 30.01% | 1.4% | 0.04% | - | 69.99% |